Novo Nordisk announced today that it plans to lower U.S. prices of several insulin products by up to 75% for those with type 1 and type 2 diabetes.
Products include pre-filled insulin pens and vials of basal, bolus and pre-mix insulins. These specifically include Levemir, Novolin, NovoLog and NovoLog Mix 70/30. Novo Nordisk also plans to reduce the price of unbranded biologics to match the lowered price of each respective branded insulin.
The price cut comes two weeks after Eli Lilly announced plans to cap out-of-pocket insulin costs at $35 with 70% price cuts. Novo Nordisk’s changes go into effect on Jan. 1, 2024.
Get the full story at our sister site, Drug Delivery Business News.